Group One Trading’s RAPT Therapeutics RAPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-200
Closed -$6.77K 8538
2025
Q4
$6.77K Buy
+200
New +$6.21K ﹤0.01% 7036
2025
Q1
Sell
-20,113
Closed -$254K 8242
2024
Q4
$254K Buy
+20,113
New +$255K ﹤0.01% 3747
2024
Q3
Sell
-3,625
Closed -$88.5K 7239
2024
Q2
$88.5K Buy
3,625
+337
+10% +$15.6K ﹤0.01% 4060
2024
Q1
$236K Buy
3,288
+1,875
+133% +$261K ﹤0.01% 3414
2023
Q4
$281K Buy
1,413
+1,163
+465% +$144K ﹤0.01% 3557
2023
Q3
$33.2K Buy
250
+212
+558% +$34.6K ﹤0.01% 5459
2023
Q2
$5.61K Sell
38
-600
-94% -$93.5K ﹤0.01% 6675
2023
Q1
$93.6K Buy
+638
New +$129K ﹤0.01% 4361
2021
Q4
Sell
-138
Closed -$34K 8737
2021
Q3
$34K Sell
138
-18,762
-99% -$4.96M ﹤0.01% 6833
2021
Q2
$4.81M Buy
+18,900
New +$3.53M 0.01% 1725

Group One Trading's RAPT Position: Q1 2026 in Review

Group One Trading sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 5,282 shares — an estimated $179K sold.

Group One Trading first reported a position in RAPT in Q4 2020 and held it in 7 quarters. The position peaked at $179K in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • Group One Trading reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 5,282 RAPT Therapeutics shares in Q1 2026, an estimated $179K.
  • Group One Trading first reported a position in RAPT Therapeutics in Q4 2020 and held it in 7 quarters.
  • Group One Trading's RAPT Therapeutics position peaked at $179K in Q4 2025.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.